Zoladex
Brain Tumor
St. Jude Children's Research HospitalPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
41 Active assets in the Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Essen Biotech | Phase 3 | BB |
Irinotecan NaviFUS Corporation | Phase 3 | BB |
Clevidipine NYU Langone Health | Phase 4 | BB |
Hydralazine NYU Langone Health | Phase 4 | BB |
LABETALOL NYU Langone Health | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Zoladex is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →